#United States #California #Pomerantz Law #Nektar Therapeutics #NKTR

Class Action Lawsuit Filed Against Nektar Therapeutics

On April 9, 2026, Pomerantz LLP disclosed a significant development in the realm of securities litigation with the filing of a class action lawsuit against Nektar Therapeutics, Inc. (NASDAQ: NKTR) and several of its top executives. The lawsuit has been lodged in the Northern District of California and is officially filed under docket number 26-cv-01951. The case is representative of individuals and entities that purchased or acquired Nektar's securities between February 26, 2025, and December 15, 2025, during which time significant alleged violations of federal securities laws took place.

Background on Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company focused on innovating therapies to modulate the immune system, particularly for treating autoimmune disorders. The company is known for its lead candidate, rezpegaldesleukin, also referred to as REZPEG or NKTR-358, which is designed to treat conditions like alopecia areata. In March 2024, the company launched a Phase 2b clinical trial called REZOLVE-AA, aimed at evaluating the effectiveness of its lead product.

Details of the Lawsuit

The crux of the lawsuit focuses on allegations that, during the class period, Nektar and its officers made materially false and misleading statements regarding the company's business practices and compliance with regulations. Specifically, the plaintiffs assert that the defendants misrepresented the integrity of the REZOLVE-AA trial's enrollment process, declaring that it adhered to proper protocol standards when evidence suggests otherwise. The false assurances provided to investors regarding the trial's prospects are central to the complaint.

Furthermore, the lawsuit reveals that the defendants claimed the enrollment complied with necessary guidelines, while the plaintiffs allege that significant lapses occurred. This oversight, they argue, could severely impact trial results as it falsely inflated the perceived efficacy of the company's treatments to investors and analysts alike.

Emergence of Concerns

The case intensified when, on December 16, 2025, Nektar released press statements reporting topline results from the REZOLVE-AA trial. It revealed that the trial did not achieve statistical significance and cited the inclusion of ineligible patients as a major factor in the unsatisfactory results. On receiving this news, Nektar's stock plummeted by 7.77%, closing at $49.16 per share, a clear indication of investor panic and loss of confidence following the damaging disclosures.

Next Steps for Investors

Investors who purchased Nektar securities during the defined class period have until May 5, 2026, to express interest in being appointed as Lead Plaintiff in the lawsuit. Interested parties can obtain the full complaint and further information by visiting the Pomerantz Law Firm's website.

Conclusion

Pomerantz LLP, recognized as a pioneer in complex securities class actions, aims to hold accountable those responsible for corporate misconduct. Having successfully secured billions in recovery for investors in the past, the firm’s involvement in this case underscores its commitment to defending the rights of those affected by alleged securities law violations. For updates and inquiries, investors can contact Danielle Peyton at Pomerantz directly.

For ongoing updates on this case and other potential class actions, stay tuned to reliable financial news sources and the Pomerantz Law Firm's announcements.